11.1 Urinary Incontinence in Men and Women, Fistulae & Urethral Diverticula

11.1 Urinary Incontinence in Men and Women, Fistulae & Urethral Diverticula

Urinary incontinence is defined by the International Continence Society (ICS) as the complaint of any involuntary loss of urine. It represents a prevalent, distressing, and economically burdensome condition affecting millions of men and women worldwide. A rigorous diagnostic evaluation is mandatory to categorize the specific subtype, identify underlying pathophysiology, rule out red flag conditions, and deliver structured evidence-based care in alignment with European Association of Urology (EAU) Guidelines.

---

1. Classification & Pathophysiology of Urinary Incontinence

Clinical management is dictated by precise pathophysiological categorization:

Stress Urinary Incontinence (SUI)

• Definition: Involuntary leakage of urine on effort or physical exertion (e.g., sporting activities, heavy lifting) or upon coughing, laughing, or sneezing.
• Female Pathophysiology:
  • Urethral Hypermobility: Loss of normal anatomical support of the urethrovesical junction and proximal urethra caused by laxity of the pubocervical fascia, arcus tendineus fasciae pelvis, and levator ani musculature (commonly following vaginal childbirth, pelvic surgery, or chronic straining). During intra-abdominal pressure spikes, the urethra rotates downward and outward without a firm "hammock" to compress against, failing to maintain positive closure pressure.
  • Intrinsic Sphincter Deficiency (ISD): Severe intrinsic dysfunction of the urethral coaptation mechanism, mucosal seal, and striated rhabdosphincter itself, often resulting from prior anti-incontinence surgery, pelvic radiation, or severe hypoestrogenism. Low ALPP (<60 cmH2O) or MUCP (<20 cmH2O) are traditional descriptions of poor urethral function, but neither is a reliable standalone diagnostic or severity threshold for choosing treatment.
• Male Pathophysiology (Post-Prostatectomy Incontinence [PPI]):
  • SUI in men occurs almost exclusively following surgical extirpation or irradiation of the prostate for benign prostatic hyperplasia (BPH) or prostate cancer (radical prostatectomy [RP]).
  • Primarily driven by direct trauma to the striated urethral sphincter (rhabdosphincter), loss of functional membranous urethral length, denervation via traction on the autonomic and pudendal branches, disruption of the puboprostatic ligaments, or bladder neck scarring.

Urgency Urinary Incontinence (UUI)

• Involuntary loss of urine accompanied by or immediately preceded by the sudden, compelling desire to pass urine that is difficult to defer (urgency).
• UUI is a clinical symptom. It can accompany detrusor overactivity (DO), defined by involuntary filling-phase contractions during urodynamics, but UUI/OAB may occur without demonstrated DO and DO may occur without leakage.

Mixed Urinary Incontinence (MUI)

• Involuntary leakage associated with both urgency and exertion/effort/coughing/sneezing.
• Management mandates identifying and treating the predominant component first (e.g., treating severe urgency medically before undertaking surgical sling procedures for minor stress leaks).

Overflow Incontinence

• Involuntary loss of urine occurring without active detrusor contraction when intravesical volume exceeds physical capacity, resulting in passive dribbling.
• Secondary to severe chronic urinary retention caused by bladder outlet obstruction (BOO; e.g., advanced BPH, urethral stricture, high-grade pelvic organ prolapse) or detrusor underactivity / acontractility (e.g., diabetic cystopathy, cauda equina syndrome, pelvic plexopathy).

Continuous & Extra-Urethral Incontinence

• Involuntary, continuous dribbling of urine bypassing the external urethral sphincter mechanism.
• Etiologies: Vesicovaginal fistula (VVF), ureterovaginal fistula, or ectopic ureter (in females, inserting into the vagina, vestibule, or distal urethra below the external sphincter, presenting with continuous incontinence despite normal, cyclic micturition).

---

2. Structured Diagnostic Evaluation

┌────────────────────────────────────────────────────────────────────────┐
│                     DIAGNOSTIC WORKUP FOR INCONTINENCE                 │
├───────────────────────────────────┬────────────────────────────────────┤
│       NON-INVASIVE ASSESSMENT     │        PHYSICAL & CLINICAL EXAM    │
├───────────────────────────────────┼────────────────────────────────────┤
│ • Detailed voiding diary (3 days) │ • Pelvic exam: Atrophy, prolapse   │
│ • Urinalysis; culture if needed  │ • Cough Stress Test (full bladder) │
│ • Pad test if needed             │ • Q-Tip Test: >30° hypermobility   │
│ • Post-Void Residual (PVR by US)  │ • Perineal / rectal neuro check    │
└───────────────────────────────────┴────────────────────────────────────┘

3-Day Bladder Diary (Frequency-Volume Chart)

• A useful part of initial assessment. Ask the patient to record the time and volume of every void, fluid intake, episodes of urgency, and leakage episodes with pad changes for at least three representative days.
• Quantifies nocturia, nocturnal polyuria (nocturnal urine volume > 20% to 33% of 24-hour output depending on age), daytime frequency, and functional bladder capacity.

Pad Testing

• Short Standardized Pad Test: A timed exercise protocol can quantify urine loss under controlled provocation; document bladder filling, duration and activity to improve reproducibility.
• 24-Hour / Longer Pad Test: Weighing pads during ordinary activities helps assess severity and treatment response. Results depend on activity and protocol. Pad tests are optional when quantification is useful; no single universal gram threshold diagnoses every patient or dictates male sling versus AUS selection.

Physical Examination & Clinical Tests

• Urinalysis: Mandatory in all patients to rule out urinary tract infection (UTI) and microscopic hematuria (which requires appropriate risk-based further evaluation).
• Cough Stress Test: Performed with a comfortably full bladder (200–300 mL) in both lithotomy and standing positions. Leakage synchronous with cough demonstrates stress leakage. Delayed leakage may suggest another mechanism, but DO requires urodynamic demonstration rather than diagnosis from timing alone.
• Cotton Swab (Q-Tip) Test: A lubricated sterile cotton swab is inserted into the female urethra to the urethrovesical junction. An angle deflection > 30° from horizontal during maximal Valsalva demonstrates urethral hypermobility.
• Post-Void Residual (PVR) Measurement: Measured via ultrasound or in-and-out catheterization. Mandatory to rule out overflow incontinence. Interpret elevated PVR in context and reassess emptying when indicated; there is no universally accepted significant-PVR cutoff in women. Monitor PVR with treatments that may worsen emptying.

---

3. Female SUI: Conservative & Medical Management

Pelvic Floor Muscle Training (PFMT)

• First-Line Standard of Care (Level 1 Evidence, EAU Strong Recommendation): Supervised PFMT must be offered to all women with SUI or MUI before considering surgery.
• Regimen: Intensive, supervised program delivered by a specialized physiotherapist for at least 3 continuous months; includes at least 8 to 12 maximal contractions held for 6 to 8 seconds, performed 3 times daily.
• Mechanism: Induces hypertrophy, increases motor unit recruitment, and elevates baseline structural support of the pubococcygeus and levator ani, facilitating conscious pre-contraction prior to intra-abdominal pressure spikes ("the Knack" maneuver).
• Biofeedback and Electrical Stimulation: Useful adjunctive modalities for patients with difficulty isolating pelvic floor musculature.

Lifestyle Modifications

• Weight Loss: Encourage weight loss in overweight/obese women; trials demonstrate improvement in UI, but the size of benefit varies between patients.
• Fluid Moderation & Caffeine Reduction: Decreases peak detrusor irritability; avoidance of constipation and smoking cessation mitigate repetitive intra-abdominal strain.

Pharmacotherapy: Duloxetine

• Mechanism of Action: A balanced serotonin-norepinephrine reuptake inhibitor (SNRI). Centrally increases concentrations of 5-HT and NE within Onuf's nucleus in the sacral spinal cord (S2–S4). Enhanced serotonergic/noradrenergic signalling increases pudendal motor output to the striated sphincter during storage.
• Clinical Application: Licensed in Europe for moderate-to-severe female SUI. EAU weakly offers it to selected women unresponsive to other conservative measures who wish to avoid invasive treatment, after careful adverse-effect counselling.
• Dosing & Side Effects: Initiated at 20 mg BID and titrated to 40 mg BID. Significant adverse effects include nausea (up to 25%), dry mouth, constipation, insomnia, somnolence, and dizziness. Discontinuation rates are high (up to 30% to 40%); abrupt withdrawal must be avoided to prevent withdrawal syndrome.

---

4. Female SUI: Surgical Interventions

When conservative measures fail, surgical intervention restores suburethral support or enhances mucosal coaptation.

                                [ SUI in Females ]
                                        │
                     ┌──────────────────┴──────────────────┐
                     ▼                                     ▼
          [ Hypermobility Dominant ]               [ Intrinsic Sphincter ]
                     │                             [ Deficiency (ISD)   ]
       ┌─────────────┴─────────────┐                       │
       ▼                           ▼                       ▼
  [ Mid-Urethral Sling ]     [ Colposuspension ]     [ Retropubic TVT /   ]
  (Retropubic TVT or          (Burch Procedure)      [ Autologous Fascial ]
   Transobturator TOT)                               [ Pubovaginal Sling  ]

Mid-Urethral Slings (MUS)

Synthetic, tension-free macroporous (Type 1) polypropylene mesh strips placed beneath the mid-urethra, providing a dynamic backboard during increased abdominal pressure:

1. Retropubic Sling (TVT - Tension-free Vaginal Tape):
   • Route: Bottom-to-top (vaginal to suprapubic) or top-to-bottom through the retropubic space of Retzius.
   • Complication Profile: Higher incidence of bladder perforation (2% to 5%), pelvic hematoma (external iliac vessel branch injury), bowel injury, and postoperative voiding dysfunction / retention. Intraoperative cystourethroscopy is required to verify absence of bladder or urethral puncture.
   • Advantages: Retropubic MUS has better long-term outcomes than transobturator MUS. Do not select treatment from ALPP alone; discuss patient factors, mesh risks and alternatives.
2. Transobturator Sling (TOT / TVT-O):
   • Route: Passes laterally through the obturator membrane and adductor muscles, bypassing the retropubic space entirely (outside-in or inside-out).
   • Complication Profile: Negligible bladder perforation risk (< 0.5%), minimal vascular or bowel injury risk; however, carries a significantly higher risk of inner thigh / groin pain, adductor tendonitis, and transient dyspareunia.
   • Limitations: Slightly lower objective cure rates in severe ISD compared to retropubic TVT.

Autologous Fascial Pubovaginal Sling (PVS)

• Harvested rectus abdominis fascia or fascia lata placed at the bladder neck / proximal urethra and secured to the anterior rectus sheath.
• Indications: The gold standard non-mesh alternative; indicated for complex recurrent SUI, prior synthetic mesh extrusion or erosion, irradiated pelvic fields, urethral reconstruction/diverticula, and neurogenic SUI.
• Complications: Higher rates of persistent voiding dysfunction, long-term clean intermittent catheterization (up to 5% to 10%), and abdominal wall harvest morbidity.

Colposuspension (Burch Procedure)

• Open, laparoscopic, or robotic suspension of the paravaginal endopelvic fascia bilaterally to Cooper's pectineal ligaments.
• High long-term efficacy without synthetic vaginal mesh exposure; carries risk of postoperative anterior vaginal wall tightening predisposing to posterior compartment prolapse (enterocele, rectocele).

Urethral Bulking Agents

• Transurethral or periurethral endoscopic injection of biocompatible polymers (e.g., cross-linked polyacrylamide hydrogel [Bulkamid], polydimethylsiloxane [Macroplastique]) into the submucosa of the proximal urethra.
• Indicated in frail or elderly patients unfit for anesthesia, or those with ISD without urethral hypermobility. Minimally invasive under local anesthesia, but confers lower long-term cure rates and often requires repeat injections.

---

5. Male SUI & Post-Prostatectomy Incontinence (PPI)

Natural History & Conservative Management

• Following radical prostatectomy, urinary control gradually improves over time as neuromuscular edema subsides and compensatory pelvic floor tone increases.
• Observation Window: Offer PFMT and follow recovery, commonly over 6–12 months. Persistent bothersome SUI merits surgical discussion at one year; earlier surgery around six months can be considered when severe leakage is not improving. Recovery trajectory and preference matter.

Male Synthetic Slings

• Suburethral transobturator mesh slings (e.g., AdVance) or adjustable slings that compress and elevate the bulbous urethra, repositioning the membranous urethral complex.
• Stringent Selection Criteria:
  • Mild-to-moderate PPI, judged using leakage, bother and functional assessment; pad count/weight can help but are not universal eligibility thresholds.
  • Preserved residual voluntary sphincter contraction confirmed on flexible urethrocystoscopy.
  • Normal bladder compliance and detrusor contractility without significant BOO.
  • Prior Radiotherapy: Counsel that radiation, severe leakage and prior urethral surgery reduce sling success. Radiotherapy is a negative prognostic factor, not an absolute EAU contraindication; AUS is generally preferred for significant post-radiation SUI.

Artificial Urinary Sphincter (AUS / AMS 800)

• Standard Intervention: Offer AUS for moderate-to-severe male SUI, including suitable men after radiotherapy. Assess urethral patency, bladder function, cognition and manual ability to operate the pump. Explain persistent leakage and future revision/explantation risks; radiation also worsens AUS outcomes.
• Device Architecture:
  1. Urethral Cuff: Inflatable silicone cuff placed around the bulbar urethra (sizes 3.5 to 5.0 cm).
  2. Pressure-Regulating Balloon (PRB): Placed in the space of Retzius (prevesical) or high submuscular space; standard pressure ranges from 61 to 70 cmH2O (rarely 71–80 cmH2O) to prevent ischemic cuff erosion.
  3. Scrotal Control Pump: Placed in a dependent, easily accessible scrotal pouch with a deactivation button.
• Activation Protocols & Operational Dynamics:
  • The device is surgically placed in a deactivated state and remains deactivated for 6 to 8 weeks postoperatively to allow complete surgical edema resolution and fibrous pseudocapsule maturation.
  • When activated, the cuff maintains continuous urethral compression. To micturate, the patient squeezes the scrotal pump, displacing fluid into the balloon. The cuff deflates, permitting unobstructed flow, and automatically refills spontaneously over 3 to 5 minutes via a fluid resistor valve.
• Complications & Emergency Management:
  • Urethral Cuff Erosion (2% to 8%): Manifests with sudden return of incontinence, hematuria, perineal pain, or failure of catheterization. Diagnosed by urethroscopy showing exposed cuff material within the urethra. Management: Complete surgical explantation of all components, prolonged catheterization (3–4 weeks), and delayed revision at a different site 3 to 6 months later.
  • Device Infection (1% to 3%): Requires prompt, complete removal of all components; primary salvage re-implantation is contraindicated in active purulent infection.
  • Mechanical Failure (5% to 15% at 5–10 years): Fluid leak from balloon or tubing requiring surgical revision.

---

6. Genitourinary & Enterovesical Fistulae

Urinary tract fistulae represent abnormal communications between the urinary tract and adjacent anatomical cavities or visceral organs, presenting with continuous incontinence or passage of enteric contents.

Vesicovaginal Fistula (VVF)

• Etiology:
  • High-Income Countries: Most are iatrogenic, resulting from unintentional injury during gynaecological surgery—predominantly total abdominal, vaginal, or laparoscopic/robotic hysterectomy—or secondary to pelvic radiation therapy for cervical or uterine malignancy.
  • Low-Income Countries: The vast majority result from obstructed, prolonged labour (ischemic pressure necrosis of the bladder neck, trigone, and anterior vaginal wall compressed against the pubic symphysis by the impacted fetal head).
• Clinical Presentation: Continuous, painless involuntary loss of urine from the vagina, often beginning 7 to 21 days after surgery (due to delayed ischemic sloughing) or immediately if there was direct laceration. Normal cyclic micturition may be absent if the defect is large.
• Diagnostic Workup:
  • Speculum Examination: Direct visual inspection of the anterior vaginal wall to localize the fistula orifice and inspect mucosal health.
  • The Classic Triple-Pad (Tampon) Test: Differentiates vesicovaginal from ureterovaginal fistula:
    1. The patient ingests oral phenazopyridine (Pyridium), which is excreted renally and turns urine bright orange.
    2. Dilute methylene blue or indigo carmine is instilled into the bladder via a transurethral catheter.
    3. Three dry cotton swabs or tampons are placed sequentially into the upper, middle, and lower vagina, and the patient ambulates for 15–30 minutes.
    4. Interpretation: If the vaginal swabs stain blue, a vesicovaginal fistula is confirmed. If the upper swab stains orange only (with no blue staining), the dye passed from the kidney via the ureter into the vagina, confirming a ureterovaginal fistula.
  • Cystourethroscopy: Accurately establishes the number of fistulae, size, relationship to the interureteric ridge, and distance from both ureteric orifices (essential to avoid ureteric compromise during suture placement).
  • Upper Tract Imaging: Assess ureteric integrity when injury is suspected. Contrast-enhanced CT with a late excretory phase is particularly useful for suspected ureterovaginal fistula; RPG can further define anatomy and permit stenting.
• Surgical Repair Principles:
  • Timing of Repair: Initially ensure urinary drainage and treat infection. Individualize definitive repair once oedema, inflammation and necrosis have resolved; early repair is possible in suitable healthy tissue. There is no mandatory 6–12-week delay for every VVF, nor a fixed 6–12-month rule for every radiation fistula.
  • Basic Tenets of Repair:
    1. Wide mobilization of bladder and vaginal walls to allow completely tension-free closure.
    2. Excision of dense avascular scar tissue at the fistula margins.
    3. Multilayered, watertight closure using fine absorbable sutures, ensuring suture lines do not overlap.
    4. Interposition of Healthy Vascularized Tissue: Particularly consider for recurrent, large, ischaemic or tenuous repairs; EAU recommends it for radiation-associated fistulae. It is not essential in every uncomplicated repair.
       • Transvaginal Repair: Martius labial fibrofatty flap (harvested from the labium majus pedicled on the posterior labial vessels).
       • Transabdominal / Laparoscopic Repair: Omental flap (or peritoneum / epiploic appendices).
    5. Continuous, uninhibited postoperative bladder decompression with a large-bore transurethral or suprapubic catheter until healing is confirmed—often 10–14 days for simple/postsurgical fistulae, longer (about 14–21 days) for complex/radiation repairs. Tailor imaging and drainage to the repair.

Ureterovaginal Fistula

• Etiology: Unrecognized intraoperative transection, ligation, or thermal devascularization of the distal pelvic ureter during gynaecological procedures (e.g., uterine artery ligation).
• Clinical Presentation: Continuous watery vaginal leakage coexisting with normal, periodic micturition (because the contralateral kidney fills the bladder normally, and some urine from the ipsilateral kidney may still reach the bladder if transection is incomplete).
• Diagnosis: CT urography (delayed excretory phase demonstrates contrast extravasation into the vaginal cuff) and retrograde ureteropyelography. Triple-pad test shows orange staining of the vaginal pad without blue staining after intravesical methylene blue instillation.
• Management:
  • Immediate attempt at retrograde Double-J ureteric stenting (or antegrade percutaneous nephrostomy stenting). Drainage and bridging stenting may allow selected injuries to heal; success depends on the injury and timing.
  • If stenting fails or complete transection has occurred: definitive surgical reconstruction via ureteroneocystostomy (ureteric reimplantation with an anti-reflux mechanism, combined with a psoas hitch or Boari flap to ensure a tension-free anastomosis).

Enterovesical & Colovesical Fistulae

• Etiology:
  • Diverticular Disease (60% to 70%): Acute sigmoid diverticulitis adhering to and rupturing into the bladder dome.
  • Colorectal Adenocarcinoma (15% to 20%): Direct malignant invasion from sigmoid or rectal carcinoma.
  • Crohn's Disease (10%): Transmural enteritis forming an ileovesical fistula.
  • Other causes: Pelvic radiotherapy, trauma, foreign bodies.
• Characteristic Signs & Clinical Presentation:
  • Pneumaturia: Passage of gas during urination strongly suggests an enterovesical communication when instrumentation and gas-forming infection are excluded.
  • Fecaluria: Passage of recognizable fecal particulate matter in the urine.
  • Gouverneur's Syndrome: Refractory, recurrent polymicrobial urinary tract infections (mixed flora with E. coli, enterococci, Bacteroides, Klebsiella), severe suprapubic pain, and irritative storage symptoms.
• Diagnostic Workup:
  • Abdominal/Pelvic CT with Oral or Rectal Contrast: The diagnostic modality of choice. Demonstrates air within the bladder lumen in the absence of recent instrumentation, thickened bowel wall adherent to the bladder dome, and passage of oral/rectal contrast into the bladder. Tailor the protocol with radiology: enteric contrast reaching the bladder is easier to identify before excreted IV contrast arrives, while IV contrast is useful for bowel inflammation, abscesses and tumour assessment. It is not generally contraindicated in fistula imaging.
  • Bourne Test: Urine is collected and centrifuged after a barium enema; radiography of the centrifuged urine pellet demonstrates radiopaque barium particles.
  • Cystoscopy: Reveals localized mucosal erythema, intense bullous edema, and an elevated papillary mucosal reaction (the "sentinel sign") classically on the left posterior wall or dome of the bladder, often with visible gas or fecal bubbles discharging from the center.
  • Colonoscopy: Mandatory to evaluate the bowel lumen and definitively rule out underlying colorectal malignancy before definitive surgery.
• Surgical Management:
  • For suitable patients, resect the diseased bowel segment, commonly sigmoid colectomy with primary anastomosis. Sepsis, tissue quality, malignancy and operative risk may instead require a staged approach.
  • The bladder defect is typically small and inflammatory; it is cleanly separated from the bowel and closed in two layers with absorbable suture (or managed by simple Foley catheter drainage if minute).
  • Omental Interposition: An omental flap may separate bowel and bladder repairs when appropriate; it is not mandatory in every case.

---

7. Female Urethral Diverticulum

An outpouching of the urethral mucosa herniating through the periurethral muscularis into the anterior vaginal space.

Pathophysiology

• Almost always acquired. Originates from infection, chronic inflammation, and recurrent obstruction of the branched periurethral glands of Skene located along the posterolateral middle and distal urethra.
• Repeated micro-abscess formation leads to cystic dilation of the gland and subsequent rupture into the urethral lumen, forming a permanent epithelialized sac communicating with the urethral canal via a narrow neck.
• Urine stasis within the diverticulum predisposes to recurrent infections, calculus formation (in 5% to 10%), and rarely malignant transformation (most commonly adenocarcinoma, including clear-cell forms; urothelial and squamous carcinomas also occur).

Clinical Presentation: The Classic "3 Ds"

1. Dysuria: Severe, persistent, or recurrent burning with micturition.
2. Dyspareunia: Pain during sexual intercourse, specifically localized to the anterior vaginal wall.
3. Post-Void Dribbling: Involuntary loss of urine occurring 5 to 15 minutes after completion of voiding, caused by passive gravitational drainage of urine pooled inside the diverticular sac.

• Additional Symptoms: Recurrent culture-positive UTIs, sensation of an anterior vaginal lump, hematuria, and chronic pelvic pain.

Physical Examination

• Palpation of the anterior vaginal wall along the course of the urethra reveals a soft, fluctuant, tender suburethral cystic mass.
• Milking the Urethra: Gentle digital compression of the mass from proximal to distal toward the external meatus characteristically expresses cloudy urine or purulent discharge from the urethral meatus, supporting communication with the urethral lumen; imaging defines the lesion and its extent.

Diagnostic Workup

• Pelvic Magnetic Resonance Imaging (MRI):
  • The gold standard for imaging urethral diverticula.
  • Performed with an endovaginal coil or high-resolution pelvic phased-array surface coil.
  • T2-weighted images demonstrate hyperintense (fluid-bright) signal within the diverticulum, exquisitely defining the size, number (single vs multiloculated), location of the diverticular neck, and circumferential morphology (e.g., "saddle-bag" or "horseshoe" configuration extending around the urethra).
  • Clearly delineates the relationship of the diverticular neck to the striated external urethral sphincter, which is paramount for preserving continence during surgical excision.
  • Detects intraluminal filling defects such as diverticular calculi or soft-tissue neoplasms (adenocarcinoma).
• Voiding Cystourethrography (VCUG) / Double-Balloon Positive-Pressure Urethrography: Historical alternatives that demonstrate contrast filling the diverticular cavity during micturition, but carry lower sensitivity for non-communicating or debris-filled diverticula.
• Urethrocystoscopy: Identifies the exact clock position of the diverticular ostium along the urethral floor, but cannot determine circumferential extent.

Surgical Management: Transvaginal Diverticulectomy

Offer expert surgical removal for bothersome symptomatic diverticula, counselling about recurrence and de novo SUI. Women with minimal symptoms may choose conservative management after counselling about the small malignancy risk. The usual definitive operation is transvaginal excision:

1. Patient Positioning & Exposure: Dorsal lithotomy position; a Foley catheter is placed into the bladder to identify the urethra.
2. Incision: An inverted U-shaped or longitudinal incision is made in the anterior vaginal wall over the diverticulum.
3. Meticulous Dissection: The periurethral fascial layer is carefully reflected from the vaginal mucosa, preserving tissue planes.
4. Sac Mobilization & Complete Excision: The diverticular sac is mobilized circumferentially down to its communicating neck at the urethral floor. The entire epithelial lining of the sac is excised.
5. Urethral Closure: The mucosal defect in the urethral floor is closed longitudinally in a watertight, tension-free fashion using fine (4-0 or 5-0) absorbable sutures over the catheter.
6. Multilayered Reconstruction: The periurethral fascia and vaginal muscularis are closed in distinct, separate layers. Crucially, the suture lines are staggered (non-overlapping) with the urethral closure to prevent postoperative urethrovaginal fistula formation.
7. Tissue Interposition: If local tissues are attenuated, scarred from prior surgery, or if a large dead space remains, a Martius fibrofatty flap is mobilized from the labium majus and interposed over the repair.
8. Postoperative Care: Continuous transurethral or suprapubic catheter drainage is maintained for 10 to 14 days, followed by a voiding cystourethrogram prior to catheter removal to verify absence of extravasation.

---

8. Comparative Clinical Matrices

Stress Urinary Incontinence: Female vs Male Management

Genitourinary Fistulae & Urethral Diverticula Summary Matrix